Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (PVT1) in human diseases  

作　　者：Fang Wu Yiping Zhu Caiping Zhou Weiwei Gui Hong Li Xihua Lin 

机构地区：[1]Department of Endocrinology,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310016,China [2]Department of General Surgery,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310016,China [3]Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310016,China

出　　处：《Genes & Diseases》2023年第3期901-914,共14页基因与疾病（英文）

摘　　要：Plasmacytoma variant translocation 1 (PVT1) is a long non-coding RNA (lncRNA) gene identified as a recurrent breakpoint of Burkitt’s lymphomas. Human PVT1 gene is located on region 8q24.21, a well-known cancer risk region, and encodes at least 26 linear ncRNA isoforms and 26 circular RNA isoforms, as well as 6 microRNAs. Several PVT1 functioning models have been reported recently such as competing endogenous RNA (ceRNA) activity and regulating protein stability of oncogenes, especially MYC oncogene. The promoter of PVT1 gene is a boundary element of tumor-suppressor DNA. CircPVT1 derived from PVT1 gene is also a critical non-coding oncogenic RNA. Although substantial advancements have been made in understanding the roles of PVT1 in cancer recently, the detailed mechanisms underlying its functions remain unclear. Herein, we summarize the recent progressions on the mechanisms underlying PVT1 regulated gene expression at different levels. We also discuss the interaction between lncRNA and protein, RNA and DNA, as well as the potential cancer therapy strategy by targeting these networks.

关 键 词：CANCER ceRNA CircPVT1 Long non-coding RNAs Micr oRNAs MYC PVT1 Regulatory mechanism 

分 类 号：R730[医药卫生—肿瘤]